Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study.
[BACKGROUND/OBJECTIVES] Based on the SPARTAN and TITAN studies, apalutamide is approved for patients with nonmetastatic castration-resistant and metastatic castration-sensitive prostate cancer.
APA
Shore N, Hafron J, et al. (2025). Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study.. Prostate cancer and prostatic diseases, 28(3), 828-831. https://doi.org/10.1038/s41391-024-00858-4
MLA
Shore N, et al.. "Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study.." Prostate cancer and prostatic diseases, vol. 28, no. 3, 2025, pp. 828-831.
PMID
38969791
Abstract
[BACKGROUND/OBJECTIVES] Based on the SPARTAN and TITAN studies, apalutamide is approved for patients with nonmetastatic castration-resistant and metastatic castration-sensitive prostate cancer. Skin rash was a common adverse reaction across indications. We hypothesized that earlier identification and intervention could improve rash outcomes.
[SUBJECTS/METHODS] A prespecified rash management guide outlining recommended skin care practices was provided to all patients enrolled in Apa-RP (NCT04523207). Rash-related safety data from Apa-RP were compared descriptively with data from SPARTAN and TITAN.
[RESULTS] Patients in Apa-RP experienced improved rash-related outcomes vs those in SPARTAN and TITAN.
[CONCLUSIONS] Increased vigilance and proactive management may reduce the incidence, severity, and duration of rash during apalutamide treatment.
[SUBJECTS/METHODS] A prespecified rash management guide outlining recommended skin care practices was provided to all patients enrolled in Apa-RP (NCT04523207). Rash-related safety data from Apa-RP were compared descriptively with data from SPARTAN and TITAN.
[RESULTS] Patients in Apa-RP experienced improved rash-related outcomes vs those in SPARTAN and TITAN.
[CONCLUSIONS] Increased vigilance and proactive management may reduce the incidence, severity, and duration of rash during apalutamide treatment.
MeSH Terms
Aged; Humans; Male; Middle Aged; Androgen Receptor Antagonists; Exanthema; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Thiohydantoins
같은 제1저자의 인용 많은 논문 (5)
- Editorial Comment on "Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer".
- Population-adjusted network meta-analyses provide new insights into the efficacy of treatment alternatives for metastatic castration-sensitive prostate cancer.
- Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis.
- Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.
- Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data.